Capula Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Capula Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$110K	Buy	+247	New	+$115K	﹤0.01%	875
2025 Q4	–	Sell	-770	Closed	-$332K	–	938
2025 Q3	$302K	Buy	770 +667	+648%	+$279K	﹤0.01%	528
2025 Q2	$45.9K	Sell	103 -170	-62%	-$78.3K	﹤0.01%	586
2025 Q1	$132K	Buy	+273	New	+$127K	﹤0.01%	591
2024 Q4	–	Sell	-174	Closed	-$80.9K	–	620
2024 Q3	$80.9K	Buy	+174	New	+$83.6K	﹤0.01%	454
2024 Q2	–	Sell	-986	Closed	-$412K	–	677
2024 Q1	$412K	Buy	+986	New	+$417K	0.01%	269
2021 Q4	–	Sell	-8,995	Closed	-$1.63M	–	781
2021 Q3	$1.63M	Buy	+8,995	New	+$1.76M	0.02%	439
2021 Q2	–	Sell	-5,547	Closed	-$1.19M	–	886
2021 Q1	$1.19M	Buy	5,547 +2,373	+75%	+$521K	0.02%	335
2020 Q4	$750K	Buy	3,174 +1,684	+113%	+$386K	0.04%	227
2020 Q3	$405K	Buy	1,490 +1,107	+289%	+$305K	0.05%	117
2020 Q2	$111K	Buy	+383	New	+$104K	﹤0.01%	297
2020 Q1	–	Sell	-14	Closed	-$3K	–	459
2019 Q4	$3K	Sell	14 -20	-59%	-$4.05K	﹤0.01%	367
2019 Q3	$6K	Buy	+34	New	+$6.01K	﹤0.01%	299

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capula Management's VRTX Position: Q1 2026 in Review

Capula Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2026: 247 shares worth $110K. The stake represents ﹤0.01% of the portfolio and ranks #875 among its holdings. This is a return to the name: Capula Management previously reported a position in VRTX as recently as Q3 2025.

Capula Management first reported a position in VRTX in Q3 2019 and has held it in 13 quarters since. The position peaked at $1.63M in Q3 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Capula Management held 247 shares of Vertex Pharmaceuticals worth $110K as of Q1 2026.
Vertex Pharmaceuticals was a new Capula Management position in Q1 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Capula Management's portfolio in Q1 2026, its #875 holding.
Capula Management first reported a position in Vertex Pharmaceuticals in Q3 2019 and has held it in 13 quarters since.
Capula Management's Vertex Pharmaceuticals position peaked at $1.63M in Q3 2021.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Capula Management's 13F filing for Q1 2026, filed 14 May 2026.